Quick Answer
Bioventus Inc. reported Total Revenue of $568.09 million for the year ending 2025.
- Bioventus Inc. showed a decrease of -0.9% in Total Revenue from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $78.65 million | Q2 2020: $58.02 million | Q3 2020: $85.91 million | Q1 2021: $81.78 million | Q2 2021: $109.82 million | Q3 2021: $108.89 million | Q1 2022: $117.29 million | Q2 2022: $140.33 million | Q3 2022: $128.66 million | Q1 2023: $119.06 million | Q2 2023: $137.07 million | Q3 2023: $120.79 million | Q1 2024: $129.46 million | Q2 2024: $151.22 million | Q3 2024: $138.96 million | Q1 2025: $123.88 million | Q2 2025: $147.66 million | Q3 2025: $138.65 million.
- Over the full 7 years of available data (2019 to 2025), Bioventus Inc.'s Total Revenue has grown by 67.0%.
- Historical annual values: Fiscal year 2025: $568.09 million | Fiscal year 2024: $573.28 million | Fiscal year 2023: $512.35 million | Fiscal year 2022: $512.12 million | Fiscal year 2021: $430.90 million | Fiscal year 2020: $321.16 million | Fiscal year 2019: $340.14 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: